Assessment of the Surveillance Interval at 1 Year after Curative Treatment in Hepatocellular Carcinoma: Risk Stratification
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Guidelines recommend surveillance for hepatocellular carcinoma (HCC) recurrence at 3-month intervals during the first year after curative treatment and 6-month intervals thereafter in all patients. This strategy does not reflect individual risk of recurrence. We aimed to stratify risk of recurrence to optimize surveillance intervals 1 year after treatment. Methods: We retrospectively analyzed 1,316 HCC patients treated with resection/radiofrequency ablation at Barcelona Clinic Liver Cancer stage 0/ A. In patients without 1-year recurrence under 3-monthly surveillance, a new model for recurrence was developed using backward elimination methods: training (n=582)/ validation cohorts (n=291). Overall survival (OS) according to risk stratified by the new model was compared according to surveillance intervals: 3-monthly versus 6-monthly (n=401) after lead time bias correction and propensity-score matching analyses. Results: Among patients without 1-year recurrence, age and international normalized ratio values were significant factors for recurrence (hazard ratio [HR], 1.03; 95% confidence interval [CI], 1.00 to 1.03; p=0.009 and HR, 5.63; 95% CI, 2.24 to 14.18; p<0.001; respectively). High-risk patients stratified by the new model showed significantly higher recurrence rates than low-risk patients in the validation cohort (HR, 1.73; 95% CI, 1.18 to 2.53; p=0.005). After propensity-score matching between the 3-monthly and 6-monthly surveillance groups, OS in high-risk patients under 3-monthly surveillance was significantly higher than that under 6-monthly surveillance (p=0.04); however, OS in low-risk patients under 3-monthly surveillance was not significantly different from that under 6-monthly surveillance (p=0.17). Conclusions: In high-risk patients, 3-monthly surveillance can prolong survival compared to 6-monthly surveillance. However, in low-risk patients, 3-monthly surveillance might not be beneficial for survival compared to 6-monthly surveillance.
Abstract
Background/Aims: Guidelines recommend surveillance for hepatocellular carcinoma (HCC) recurrence at 3-month intervals during the first year after curative treatment and 6-month intervals thereafter in all patients. This strategy does not reflect individual risk of recurrence. We aimed to stratify risk of recurrence to optimize surveillance intervals 1 year after treatment. Methods: We retrospectively analyzed 1,316 HCC patients treated with resection/radiofrequency ablation at Barcelona Clinic Liver Cancer stage 0/ A. In patients without 1-year recurrence under 3-monthly surveillance, a new model for recurrence was developed using backward elimination methods: training (n=582)/ validation cohorts (n=291). Overall survival (OS) according to risk stratified by the new model was compared according to surveillance intervals: 3-monthly versus 6-monthly (n=401) after lead time bias correction and propensity-score matching analyses. Results: Among patients without 1-year recurrence, age and international normalized ratio values were significant factors for recurrence (hazard ratio [HR], 1.03; 95% confidence interval [CI], 1.00 to 1.03; p=0.009 and HR, 5.63; 95% CI, 2.24 to 14.18; p<0.001; respectively). High-risk patients stratified by the new model showed significantly higher recurrence rates than low-risk patients in the validation cohort (HR, 1.73; 95% CI, 1.18 to 2.53; p=0.005). After propensity-score matching between the 3-monthly and 6-monthly surveillance groups, OS in high-risk patients under 3-monthly surveillance was significantly higher than that under 6-monthly surveillance (p=0.04); however, OS in low-risk patients under 3-monthly surveillance was not significantly different from that under 6-monthly surveillance (p=0.17). Conclusions: In high-risk patients, 3-monthly surveillance can prolong survival compared to 6-monthly surveillance. However, in low-risk patients, 3-monthly surveillance might not be beneficial for survival compared to 6-monthly surveillance.
참고문헌 (28)
- Ikai I, "Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan", Hepatol Res, 37, pp.676~691 (2007)[DOI]
- European Association for the Study of the Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)[DOI]
- Yu SJ, "A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016", Clin Mol Hepatol, 22, pp.7~17 (2016)[DOI]
- Kumada T, "Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma", Hepatology, 25, pp.87~92 (1997)[DOI]
- Adachi E, "Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma", Gastroenterology, 108, pp.768~775 (1995)[DOI]
- Okada S, "Predictive factors for postoperative recurrence of hepatocellular carcinoma", Gastroenterology, 106, pp.1618~1624 (1994)[DOI]
- Belghiti J, "Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis", Ann Surg, 214, pp.114~117 (1991)[DOI]
- Llovet JM, "Resection and liver transplantation for hepatocellular carcinoma", Semin Liver Dis, 25, pp.181~200 (2005)[DOI]
- Balsells J, "Resection of hepatocellular carcinoma in patients with cirrhosis", Br J Surg, 83, pp.758~761 (1996)[DOI]
- Chen MF, "Postoperative recurrence of hepatocellular carcinoma: two hundred five consecutive patients who underwent hepatic resection in 15 years", Arch Surg, 129, pp.738~742 (1994)[DOI]
- Lau H, "Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients", Cancer, 83, pp.2302~2311 (1998)[DOI]
- Takenaka K, "Results of 280 liver resections for hepatocellular carcinoma", Arch Surg, 131, pp.71~76 (1996)[DOI]
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)[DOI]
- Kim SU, "Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis", PLoS One, 7, pp.e36676~ (2012)[DOI]
- Adams PC, "Screening in liver disease: report of an AASLD clinical workshop", Hepatology, 39, pp.1204~1212 (2004)[DOI]
- Schwartz M, "A biomathematical approach to clinical tumor growth", Cancer, 14, pp.1272~1294 (1961)[DOI]
- Sheu JC, "Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications", Gastroenterology, 89, pp.259~266 (1985)[DOI]
- Ng KK, "Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma", Br J Surg, 104, pp.1775~1784 (2017)[DOI]
- Majumdar A, "Management of people with early- or very earlystage hepatocellular carcinoma: an attempted network metaanalysis", Cochrane Database Syst Rev, 3 (2017)
- Wang Y, "Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials", PLoS One, 9, pp.e84484~ (2014)[DOI]
- Livraghi T, "Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?", Hepatology, 47, pp.82~89 (2008)
- Shim JH, "Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma", Ann Surg, 261, pp.939~946 (2015)[DOI]
- Rodriguez-Peralvarez M, "A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability", Ann Surg Oncol, 20, pp.325~339 (2013)[DOI]
- Fan L, "Interobserver and intraobserver variability in evaluating vascular invasion in hepatocellular carcinoma", J Gastroenterol Hepatol, 25, pp.1556~1561 (2010)[DOI]
- Mittal S, "Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: a United States cohort", J Hepatol, 65, pp.1148~1154 (2016)[DOI]
- Santi V, "Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival", J Hepatol, 53, pp.291~297 (2010)[DOI]
- van Meer S, "Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands", J Hepatol, 63, pp.1156~1163 (2015)[DOI]
- Sangiovanni A, "Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance", Gastroenterology, 126, pp.1005~1014 (2004)[DOI]